Research Overview

Four platforms. One manufacturing backbone.

Every program we run shares the same iPSC manufacturing infrastructure — from initial reprogramming and quality testing to cGMP-grade scale-up and IND-enabling CMC.

01

The foundational layer for everything we build.

iPSC Platform & Cell Differentiation

Our iPSC core operates as the backbone of every therapeutic program — from cGMP-grade reprogramming and banking to scalable directed differentiation into clinically relevant cell types. We maintain the world's largest ALS patient iPSC biorepository and have established robust protocols across cardiovascular, neurological, and metabolic lineages.

cGMP iPSC BankingEndothelial DifferentiationIslet β-cellNeural / Motor NeuronCardiomyocytesBioreactor Scale-UpDisease Modeling Lines
Explore platform
02

Engineering cells that do what drugs cannot.

Cell & Gene-Edited Therapies

We engineer hypoimmune, off-the-shelf cell therapies using CRISPR-based gene editing to create universal donor iPSC lines. Our pipeline spans vascular progenitors for critical limb ischemia, insulin-secreting beta cells for T1D, and CAR-T/NK platforms for immuno-oncology — all supported by IND-enabling CMC infrastructure at our cGMP facility.

Hypoimmune EngineeringVascular ProgenitorsIslet Cell TherapyImmunotherapyCardiac Cell TherapyCRISPR EditingIND-Enabling CMC
Explore platform
03

Building complexity from the ground up.

Bioengineered Tissues & Organoids

From vascularized cardiac constructs to bioengineered pancreas systems, we build multi-cellular tissue architectures that recapitulate native organ physiology. Our organ-on-chip and organoid platforms serve as next-generation alternatives to animal models (NAMs) for disease modeling and drug screening.

Vascularized Cardiac TissueCardiomyocyte Disease ModelsPrevascularized ConstructsVascular OrganoidsBioengineered PancreasOrgan-on-ChipBiomaterial ScaffoldsNAMs Platforms
Explore platform
04

Making cell therapy as reliable as semiconductor fabrication.

Robotics, Automation & AI

We're building closed-loop, AI-integrated biomanufacturing infrastructure where robotic systems handle iPSC reprogramming, differentiation, and QC — eliminating batch-to-batch variability. Machine learning models score colony morphology, predict process deviations, and optimize bioprocess parameters in real time.

Automated iPSC ReprogrammingAutologous ManufacturingRobotic DifferentiationModular Gene EditingML Process OptimizationReal-Time CQA MonitoringDigital TwinsAI Colony Scoring
Explore platform

Disease Focus

Active therapeutic programs.

Critical Limb IschemiaType 1 DiabetesCardiomyopathyALSSpinal Muscular AtrophyImmuno-Oncology
Cardiovascular DiseaseMetabolic DisordersNeurodegenerative Disease